A clinical trial referencing LL-37 was updated on April 13, 2026. The study, registered as NCT05054361, is titled "Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children." The trial's current status is listed as recruiting. No phase designation was provided in the available record. LL-37 remains classified as an unapproved compound used in research settings only. The study is registered publicly on ClinicalTrials.gov under the identifier NCT05054361. No outcome data, efficacy claims, or safety findings have been reported as part of this update. The listing reflects only the recruitment status and study title as recorded on the given date. Researchers or participants seeking further detail can consult the official ClinicalTrials.gov entry for enrollment criteria and study design. This brief does not characterize any results, benefits, or risks associated with LL-37 in this context, as none were included in the source record. For general background on LL-37, readers can refer to the compound overview.
LL-37 Featured in Recruiting Trial NCT05054361 on Type 1 Diabetes
Source: https://clinicaltrials.gov/study/NCT05054361